Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × entrectinib × Thoracic × Clear all

Phase

Phase 2 4 Phase 3 2 Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2 Lymphoid 2 Thoracic 1 Dermatologic 1 CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 23 Carboplatin 21 Cisplatin 20 pembrolizumab 15 Docetaxel 14 Paclitaxel 10 Gemcitabine 8 Drug Therapy 7 Bevacizumab 7 Gefitinib 5 Radiotherapy 4 Magnetic Resonance Spectroscopy 4 Erlotinib Hydrochloride 4 130-nm albumin-bound paclitaxel 4 cemiplimab 3 atezolizumab 3 anlotinib 3 Dexamethasone 3 dexamethasone acetate 2 dexamethasone 21-phosphate 2 cobimetinib 2 auricularum 2 aumolertinib 2 apatinib 2 Vemurafenib 2 Topotecan 2 Temozolomide 2 Surgical Procedures, Operative 2 Standard of Care 2 Specimen Handling 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03178552 2026-03-09

B-FAST

Hoffmann-La Roche

Phase 2/3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡